NCT06843447 2026-03-27
MK-5909-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT03734692 2026-02-12
Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
University of Pittsburgh
Phase 1/2 Active not recruiting
NCT07295132 2025-12-19
RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse)
Asan Medical Center
Phase 2 Not yet recruiting
NCT06014528 2025-04-30
IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
InxMed (Shanghai) Co., Ltd.
Phase 2 Recruiting
NCT06791460 2025-03-18
Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
Phase 2/3 Recruiting
NCT04175470 2025-01-03
Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer
Vejle Hospital
Phase 2 Completed
NCT06660511 2024-10-28
Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.
Second Xiangya Hospital of Central South University
Phase EARLY_PHASE1 Recruiting
NCT06102707 2023-10-26
The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients
Qilu Hospital of Shandong University
Phase NA Not yet recruiting
NCT05095558 2021-10-27
Microtransplantation for Ovarian Cancer
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 1/2 Unknown
NCT03717610 2021-10-08
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
Uppsala University Hospital
Phase NA Unknown
NCT04072263 2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2 Unknown
NCT01111903 2016-03-17
REV
ARCAGY/ GINECO GROUP
Phase 1/2 Completed
NCT01332656 2015-12-21
OPSALIN
Sanofi
Phase 2 Completed
NCT01485848 2014-06-10
ESP2011-002
Esperance Pharmaceuticals Inc
Phase 2 Completed